Navigation Links
VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
Date:3/28/2008

ing the massive destruction of CD4 T cells, and also to halt the subsequent slow destruction of the immune system by the latently dormant virus. Individuals will be protected but not totally sterilized, minimizing the likelihood of new infections.

"The use of a HIV-based lentiviral vector represents a truly innovative approach to anti-HIV vaccine and to all vaccination strategies in general. With VRX1023 in particular, we are turning HIV against itself. We are exploiting the virus ability to efficiently produce proteins for vaccination purposes," said Riku Rautsola, PhD, President and CEO of VIRxSYS. "VRX1023 presents us with a renewed hope for the delivery of an anti-HIV vaccine."

About VIRxSYS

VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which, VRX496, has advanced to Phase 2 human clinical trials. More information regarding VIRxSYS can be found at http://www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.

Contact: Jeneane Smith / Russell LaMontagne

Phone: 212.255.5340


'/>"/>
SOURCE VIRxSYS
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...- Oramed,Pharmaceuticals, I...developer,of oral delivery systems, announced toda... Assess the Safety, Pharmacokinetics (PK) and,Phar...s in Healthy,Subjects," has been chosen for presen...European Association for the Study of Diabetes (EA...
(Date:8/17/2008)...nhua-- Pharmaxis,(ASX: PXS;...tal Phase 3,clinical trial of Bronchitol for the t...t., The first efficacy data from the trial is exp...9. The trial commenced its dosing phase in,April 2... subjects in June,2008 and closed today with 325 s...
(Date:8/14/2008)...BiTE) showing clinical benefit in cancer,patients;...gnize and attack canc...tCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a bioph...,antibodies for the treatment of cancer, inflammat...cation of a Phase 1 clinical study(1) on its,BiTE(...
(Date:8/13/2008)...irstCall/ -- As biotechnology,pharmaceutical and ...l,trials beyond their own borders to other parts o...h America, complicated regulatory environments,cha...ing to an analysis by,Aon Corporation (NYSE: AOC ...ose companies a visual representation of the compl...
Breaking Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Healthcare M 26A Activity on the Rise 9649 1Healthcare M 26A Activity on the Rise 9649 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 1Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 3New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 1New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 2Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 1Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 2
...ch 12, 2007: Progen Industries Limited,(ASX: PGL; ...8,Phase II liver cancer data has been accepted for...ssociation for the Study of the Liver,(EASL). Prog...er,cancer trial at the American Association for Ca...xpectation of having final data fully analysed and...
...d Safety Profile and Excellent,Pharmacokinetic Pro... 2007 /PRNewswire/ --,CeNeRx BioPharma, Inc., a cl...g innovative treatments for diseases of the centra... from a Phase I,clinical trial of Tyrima(TM), its ... anxiety. In this study, Tyrima was safe and well,...
Other Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:8/20/2008)...usetts General Hospital (MGH) investigators have f...em cell appeared to protect gastrointestinal tissu...ir report published in the journal Stem Cells , t...icine report that mesenchymal stem cells (MSCs), k...allowed the regeneration of the gastrointestinal l...
(Date:8/20/2008)...NGTON, Aug. 20 /PRNewswire-USNewswire/ -- Yesterda... admitted to Huron Hospital after,suffering an ane...Ohio. At,the present time Rep. Tubbs Jones, condit...are available., Tuesday,s condition followed a fu...ming forum on electoral reform, scheduled for Sept...
(Date:8/20/2008)... Micro(R) PUMP and ELLEgirl.com Send Four Girls to...Summer, LOS ANGELES, Aug. 20 /PRNewswire/ -- Reti...eenage Web site ELLEgirl.com to send four contest,...Camp in Santa Monica,California. With the new sch...mpower girls to become successful women by helping...
(Date:8/20/2008)...IEGO, Aug. 20 /PRNewswire/ --You,re late for work,...r car won,t start. How do you deal with,the rising...ash out in,frustration, how you deal with anger af...r children and even your career., As hard as we m...push,our buttons. While feeling anger isn,t a bad ...
Breaking Medicine News(10 mins):Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 2Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 4Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 5Health News:Taming Your Temper: Learning to Turn Down the Heat 2
...lips who was on his way to becoming a lawyer says ...// “The top step had ice, and I went straight over...urs, and when they found me, I had blood coming ou... recollection for two and a half years after that ...
... their risk of birth defects. Now, new research sh...e.// Researchers say about 31,000 stroke-related d...s may have been prevented each year since fortific...s homocysteine levels. People with higher homocyst...
...esearchers say the estrogen pills do not reduce th...ed risk of stroke.// Researchers say their result...or decrease the risk of heart disease as combinati...trogen also does not appear to affect a woman’s ri...
...could help fight another. Researchers say the litt...G , may hold a key to helping researchers devise n...results from the Multicenter Acquired Immunodefici...estigators followed a large group of HIV-infected ...
Other Medicine News:
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: